Abstract
Background: Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy. Case presentation: We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy. Conclusion: Here we demonstrate the safe use of dupilumab in pregnancy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.
Author supplied keywords
Cite
CITATION STYLE
Akhtar, N. H., Khosravi-Hafshejani, T., Akhtar, D., Dhadwal, G., & Kanani, A. (2022). The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. Allergy, Asthma and Clinical Immunology, 18(1). https://doi.org/10.1186/s13223-022-00650-w
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.